Peptide Receptor Radionuclide Therapy Market, by Drug Class (Lutetium, Yttrium-90, Indium-111, and others), By Disease Indication, By Distribution Channel, by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

PUBLISHED: May 18, 2023

PAGES: 170 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Peptide receptor radionuclide therapy (PRRT) is a molecular therapy (radioisotope therapy) used for the treatment of cancer associated with neuroendocrine tumors (NETs). In PRRT, peptides (cell targeting peptide) combine with a small amount of radioactive material to produce radiopharmaceutical product called radio peptide. PRRT can be also considered as personalized cancer therapy, as radio peptide can be altered into the unique biologic characteristics of the patient and the molecular properties of the tumor.

Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding and retention. The only target that is currently used in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells, including neuroendocrine tumors and neural-crest derived tumors. According to National Institute of Health (NIH) academia played an important role in the development of PRRT, which has led to heterogeneous literature over the last two decades, as no standard radiopharmaceutical or regimen has been available for a long time.

Key features of the study:

This report provides in-depth analysis of the global peptide receptor radionuclide therapy market, and provides market size (US$ million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Peptide Receptor Radionuclide Therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG (Advanced Accelerator Applications, S.A.), ITM Solucin, and Australasian Gastro-Intestinal Trials Group
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Global Peptide Receptor Radionuclide Therapy Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Peptide Receptor Radionuclide Therapy Market

Detailed Segmentation:

Global Peptide Receptor Radionuclide Therapy Market, By Drug Type:
- Lutetium (Lu-177)-based
- Yttrium-90
- Indium-111
- Others
Global Peptide Receptor Radionuclide Therapy Market, By Disease Indication:
- Pancreatic - Neuroendocrine Tumor
- Gastrointestinal Tract - Neuroendocrine Tumor
- Others
Global Peptide Receptor Radionuclide Therapy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Peptide Receptor Radionuclide Therapy Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Novartis AG
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- ITM Solucin
- Australasian Gastro-Intestinal Trials Group

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI2731

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Key Developments
Recent Product Launches/Approvals
Technological Landscape
Merger, Acquisition, Collaborations Scenario
Regulatory Scenario
PEST Analysis
Porter's Five Forces Analysis
Pricing Analysis
Brand Analysis

4. Global Peptide Receptor Radionuclide Therapy Market - Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Peptide Receptor Radionuclide Therapy Market, By Drug Type, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Lutetium (Lu-177)-based
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Yttrium-90
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Indium-111
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Others
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends

6. Global Peptide Receptor Radionuclide Therapy Market, By Disease Indication, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Pancreatic - Neuroendocrine Tumor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Gastrointestinal tract - neuroendocrine tumor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Peptide Receptor Radionuclide Therapy Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Peptide Receptor Radionuclide Therapy Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
China
Japan
India
Australia
ASEAN
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Novartis AG (Advanced Accelerator Applications, S.A.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
ITM Solucin.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Australasian Gastro-Intestinal Trials Group
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies